Nurix Therapeutics Q2 2024 GAAP EPS $(0.71) Misses $(0.63) Estimate, Sales $12.092M Miss $22.105M Estimate
Nurix Therapeutics Q2 2024 GAAP EPS $(0.71) Misses $(0.63) Estimate, Sales $12.092M Miss $22.105M Estimate
nurix therapeutics 2024年Q2 GAAP每股收益$(0.71)，未達$(0.63)的預期，銷售額爲1209.2萬美元，未達到2210.5萬美元的預期
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.63) by 12.7 percent. This is a 57.78 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $12.092 million which missed the analyst consensus estimate of $22.105 million by 45.30 percent. This is a 60.58 percent decrease over sales of $30.676 million the same period last year.
Nurix Therapeutics（納斯達克股票代碼：NRIX）報告季度每股虧損0.71美元，比分析師預估的每股虧損0.63美元低12.7％。相對去年同期每股虧損0.45美元，該數字下降了57.78％。公司報告了1209.2萬美元的季度銷售額，相比分析師預估的2210.5萬美元低了45.30％。這是去年同期銷售額3067.6萬美元的下降了60.58％。